

From: RxBulletin [mailto:mail@senderauthenticated.com] On Behalf Of RxBulletin
Sent: [Date]
To: [Pharmacist] - can they do ARIEL?
Subject: TBD

Email not displaying correctly? [View as a webpage.](#)



BROUGHT TO YOU BY

EXALGO
(hydromorphone HCl) (CII)
Extended-Release Tablets



COVIDIEN

Mallinckrodt

NOW AVAILABLE:

EXALGO® 32 mg Extended-Release Tablets

Introducing the new 32 mg EXALGO Tablet

- All EXALGO tablet strengths available in 100-count bottles

Go to [McKesson Connect](#) to order EXALGO today.

Product Description	NDC #	McKesson Item #
EXALGO 8 mg	23635-408-01	1925809
EXALGO 12 mg	23635-412-01	1928712
EXALGO 16 mg	23635-416-01	1925916
EXALGO 32 mg	23635-432-01	2007615

INDICATION

EXALGO® (hydromorphone HCl) Extended-Release Tablets (CII) is indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

IMPORTANT RISK INFORMATION

WARNING: POTENTIAL FOR ABUSE, IMPORTANCE OF PROPER PATIENT SELECTION AND LIMITATIONS OF USE

Abuse Potential

EXALGO contains hydromorphone, an opioid agonist and a Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit. Assess each patient's risk for opioid abuse or addiction prior to prescribing EXALGO. The risk for opioid abuse is increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depressive disorder). Routinely monitor all patients receiving EXALGO for signs of misuse, abuse, and addiction during treatment.

Life-threatening Respiratory Depression

Respiratory depression, including fatal cases, may occur with use of EXALGO, even when the drug has been used as recommended and not misused or abused. EXALGO is for use in opioid tolerant patients only. Proper dosing and titration are essential and EXALGO should be